The first patenting to emerge from Filtro Medical Inc. describes the development of blood filtration devices designed to reduce systemic exposure to chemotherapy or other therapeutic agents that have been delivered into a target treatment location.
Prior work has unveiled increased levels of inosine monophosphate dehydrogenase 2 (IMPDH2) expression correlating with tumor progression and poor prognosis in several diseases. A team of researchers in China have now aimed to study IMPDH2’s role in hepatoblastoma.
Work at Wake Forest University has led to the development of an H2O2-responsive doxorubicin hybrid codrug able to release H2S (acting as cardioprotective agent). They are reported to be useful for the treatment of cancer.
Some cancers with a poor prognosis have had no new treatments in decades. Advances in the genetic characterization of these tumors now offer a range of possibilities for the development of new therapies that could completely change the quality of life and survival of these patients.
Some cancers with a poor prognosis have had no new treatments in decades. Advances in the genetic characterization of these tumors now offer a range of possibilities for the development of new therapies that could completely change the quality of life and survival of these patients.
Doxorubicin is widely used as an anticancer agent, but it is associated with cardiotoxicity. Follistatin like 3 (FSTL3) is known to be involved in the regulation of cardiac hypertrophy and heart failure.
A number of possible mechanisms have been explored, but there is still no safe, reliable and universally applicable method for delivering drugs across the blood-brain barrier (BBB) to treat central nervous system diseases. Now researchers have succeeded in tuning the effect of methamphetamine, a cause of BBB breakdown, enabling brain penetration of small molecules and therapeutic proteins, without damaging the epithelial cells that constitute the main physical element of the barrier.
A team led by researchers at Washington State University (WSU) has developed a nanoparticle technology to deliver cell-killing drugs to shut down the overactive immune response that can cause damage or death in diseases like stroke and sepsis without affecting other cell types or compromising the immune system.
